• Benoît Baras, Leon de Waal, Koert J Stittelaar, Valérie Jacob, Sandra Giannini, Edwin J B Veldhuis Kroeze, Judith M A van den Brand, Geert van Amerongen, James H Simon, Emmanuel Hanon, Sally P Mossman, and Albert D M E Osterhaus.
• GlaxoSmithKline Biologicals, Rixensart, Belgium. benoit.baras@gskbio.com
• Vaccine. 2011 Mar 3; 29 (11): 2120-6.

AbstractIn the context of an A/H1N1 influenza pandemic situation, this study demonstrates that heterologous vaccination with an AS03-adjuvanted 2008/2009 seasonal trivalent and pandemic H5N1 monovalent split vaccine conferred partial protection in influenza-naïve ferrets after challenge with the influenza pandemic H1N1 A/The Netherlands/602/09 virus. Further, unlike saline control and non-adjuvanted vaccine, it was shown that immunization of naïve ferrets with an AS03-adjuvanted pandemic H1N1 A/California/7/09 influenza split vaccine induced increased antibody response and enhanced protection against the challenge strain, including significant reduction in viral shedding in the upper respiratory tract and reduced lung pathology post-challenge. These results show the need for vaccination with the adjuvanted vaccine to fully protect against viral replication and influenza disease in unprimed ferrets.Copyright © 2011 Elsevier Ltd. All rights reserved.

25 keywords...

hide…